Highlights
- 1Life science alliance · 2020
- 2Blood · 2023
- 3Cell reports. Medicine · 2025
Publications
371 publications
Funding
46 grantsView NIH portfolio on RePORTER ↗
Active
15 grants- Sub-PIThe ERADICATE follicular lymphoma consortium: accelerating improved outcomes for FL patientsLeukemia & Lymphoma Society · 2026–2030 · via Josep Carreras Leukaemia Research InstituteJCLRI 261665-01
- Co-ISPORE: Adressing Health Disparities in LymphomaNational Cancer Institute · 2025–2030 · via MD Anderson Cancer Center· 2 renewalsU54CA302435-01
- Co-ITargeting the BCL2 immune checkpoint to enhance the immunostimulatory effects of radiation in breast cancerNational Cancer Institute · 2023–2028
- KPTargeting Unmet Needs For B-cell LymphomasLeukemia & Lymphoma Society · 2022–2027LLS 7027-23 Project 1
- Co-ITargeting the microenvironment to increase immunity and immunotherapy response in DLBCLLeukemia & Lymphoma Society · 2024–2027LLS 6695-25
- MPIThe impact of changes in chromatin architecture on cancer phenotypes and tumor progressionNational Cancer Institute · 2019–2027 · via New York University· 2 renewalsP01CA229086-07
- KPBiomarkers of response in primary mediastinal B-cell lymphoma: Defining tumor microenvironment signaturesHyundai Hope on Wheels Foundation · 2024–2026HHWF 240412-01
- KPTargeting latency switch for the treatment of EBV-associated lymphomasAmerican Cancer Society · 2024–2026PF-23-1143526-01-IBCD
- Sub-PITranslational Discovery in Peripheral T-Cell LymphomasLeukemia & Lymphoma Society · 2022–2026 · via Memorial Sloan Kettering Cancer CenterLLS SCOR -7026-21
- Co-IConverting HR+ Breast Cancer Into an Individualized VaccineU.S. Department of Defense · 2019–2026W81XWH-19-1-0141
- Co-ITherapeutic targeting of breast cancer and host immune responses at inflection points in the disease trajectoryU.S. Department of Defense · 2021–2026W81XWH-21-2-0034
- Co-IEpigenetic basis and therapeutic targeting of the unique lymphoma immunological nicheNational Cancer Institute · 2024–2026P01CA272295-02
- Co-IThe Lymphoma Epidemiology of Outcomes (LEO) Cohort StudyNational Cancer Institute · 2015–2026 · via Mayo Clinic· 2 renewalsU01CA195568-09
- Co-IRole of the stromal microenvironment in B-cell lymphoma progression and immune escapeNational Cancer Institute · 2019–2025
Completed grants (31)
- KPCharacteristics and Outcomes of Patients with Follicular Lymphoma with at Least Two Prior Lines of Systemic Therapy and Treated at Cancer Centers within the LEO CohortGenentech, Inc. · 2022–2025 · via Mayo ClinicContractSRA 223443-01
- Co-IMechanism-Based Targeting of Mantle Cell LymphomaNational Cancer Institute · 2018–2025P01CA214274-05
- Sub-PIGenetic Mutational and Expression Landscape of Cutaneous CD30+ Lymphoproliferative Disorders.National Cancer Institute · 2023–2025 · via Beckman Research Institute of the City of HopeR21CA259932-02
- Co-IThe effects of immunosuppression on SARS-CoV-2 persistence, virus genetic diversity and clinical outcomes of COVID-19National Institute of Allergy and Infectious Diseases · 2024–2024R21AI182901-01
- KPImmunologic Eradication of Myeloproliferative Neoplasm Stem CellsDaedalus Fund for Innovation (Weill Cornell) · 2022–2024BioPharma AllianceBP 226449-02
- KPGeneration of fully humanized murine avatars of B-ALL patients for the study of refractoriness and relapse in a bedside approachAmerican Italian Cancer Foundation · 2023–2024AICF 230997-01
- Sub-PIMolecular Diagnosis, Prognosis and Therapeutic Targets in Lymphoma (Core 3)National Cancer Institute · 2018–2024 · via Mayo ClinicP01CA229100-05
- Co-ITargeting Genomic, Metabolic and Immunological Vulnerabilities of Colorectal CancerAmerican Association for Cancer Research · 2017–2024 · via Sloan-Kettering Institute for Cancer ResearchSU2C-AACR-DT22-17
- PIVividion Therapeutics Biopharma AgreementVividion Therapeutics, Inc. · 2023–2023BioPharma AllianceVTI 228436-01
- KPDEVELOPMENT OF NEW MODELS OF THYMIC EPITHELIAL TUMORSThymic Carcinoma Center · 2022–2023TCC 222040-01
- MPILongitudinal functional genomics in mantle cell lymphoma therapy and drug resistanceLeukemia & Lymphoma Society · 2018–2023LLS 180078-01
- Co-IHarnessing the CRL4 Ubiquitin Ligase for Antagonizing Colorectal CarcinogenesisNational Cancer Institute · 2017–2023R01CA213992-01
- KPModulation Of Viral Latency In EBV+ Lymphomas To Sensitize Tumors To ImmunotherapyAmerican Society of Hematology Inc · 2021–2023ASH 210413-01
- PIInghirami Kymera BPKymera Therapeutics, Inc. · 2021–2023BioPharma AllianceBP 214958-01
- PIC4 Therapeutics BioPharmaC4 Therapeutics · 2021–2023BioPharma AllianceBP 214989-01
- Co-IOptimization of immune checkpoint inhibition during radiation-induced vaccination in breast cancerBreast Cancer Research Foundation · 2019–2022BCRF-20-053
- MPIDefining and Targeting the JAK/SYK Pathways in Gamma Delta T-Cell LymphomasNational Cancer Institute · 2020–2022 · via Memorial Sloan Kettering Cancer CenterP50CA192937-05
- Co-IClinical and Translational Science Center - UL1National Center for Advancing Translational Sciences · 2017–2022UL1TR002384-01
- Sub-PITranslational Discovery in Peripheral T-Cell LymphomasLeukemia & Lymphoma Society · 2021–2022 · via Dana-Farber Cancer InstituteLLS 7026-21
- KPTargeting Unmet Clinical Needs for B-Cell LymphomaLeukemia & Lymphoma Society · 2016–20217012-16 CORE A
- PIPRMT5 Proposal in Lymphoproliferative DisordersPrelude Therapeutics Incorporated · 2020–2021BioPharma AlliancePTI 211559-01
- Sub-PINo. S19-049 for the Acquisition of Refractory Biospecimens (PTCL cases)National Cancer Institute · 2019–2021 · via Memorial Sloan Kettering Cancer CenterHHSN261201500003I
- PIIdentification of transcriptional determinants of asparaginase sensitivity in leukemiasStarr Cancer Consortium · 2019–2021I12-0063
- Co-ITargeting the Epithelial to Mesenchymal Transition-Related Chemoresistance in Breast CancerNational Cancer Institute · 2016–2021R01CA205418-03
- Sub-PICore C: Translational Discovery in Peripheral T-Cell LymphomasLeukemia & Lymphoma Society · 2015–2020 · via Dana-Farber Cancer Institute7011-16 CORE C
- Sub-PIProject 1: Translational Discovery in Peripheral T-Cell LymphomasLeukemia & Lymphoma Society · 2015–2020 · via Dana-Farber Cancer Institute7011-16 PROJECT 1
- PISRA Amendment No. 1 extending term to 2020.Affimed · 2019–2020ContractSRA 193797-01
- Co-ITargeting epigenetic regulator PRC2 as a therapy for established metastasisMETAvivor Research and Support, Inc. · 2018–2020MRS 183299-01
- MPILETSSGO: LYMPHOMA-ON-CHIP ENGINEERED TECHNOLOGY FOR SINGLE-ORGANOID SEQUENCING AND GENOMICSNational Cancer Institute · 2017–2020 · via Cornell University - IthacaR33CA212968-03
- Co-IOptimization of Immune Checkpoint Inhibition During Radiation-Induced Vaccination in Breast CancerBreast Cancer Research Foundation · 2018–2019BCRF 17-053
- Co-IA rational immuno-oncology strategy to target tumor associated stromal cells using untibodies.Sanofi S.A. · 2016–2017ContractSanofi RAA
Clinical research
2 studies
Active
2 studies- PIRetrospective longitudinal tissue evaluation of lung cancer patients who receive standard/immune-based, post-operative systemic therapy, and/or who undergo recurrence or progressionWeill Medical College of Cornell University · OPEN TO ACCRUAL (as of 2025)
- PIEvaluation of the BD OneFlow Acute Leukemia Panel (BD OneFlow ALOT, BCP-ALL T1, and AML T1-T4) on the BD FACSLyric Flow Cytometer using Leftover, De-identified SpecimensBecton, Dickinson and Company · OPEN TO ACCRUAL (as of 2022)
Available technologies
1 technologyView full WCM portfolio ↗
News mentions
1 mentionView all WCM news ↗
- Tumor Microenvironment Seen as a New Player in Aggressive LymphomasFebruary 4, 2021
The environment surrounding the cancerous cells of a lymphoma tumor has a strong influence on the progression of these blood-cell cancers and their responses to therapies.
Mentoring
3 menteesAll publications with mentees →
- MTMaria Teresa CacciapuotiPostdoc mentee · 2021–2022
- GAGiuseppina AstonePostdoc mentee · 2021–2023
- GZGiorgia ZanettiPostdoc mentee · 2021–2022
External relationships
Other
Daiichi Sankyo, Inc.